Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
(NASDAQ:BIIB) – Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –
Related Questions
What potential impact could the 3‑year open‑label extension data on Zorevunersen have on Biogen’s (BIIB) stock price in the short term?
How does Zorevunersen’s efficacy and safety profile compare to existing and pipeline treatments for Dravet syndrome and other epilepsies?
What are the expected timelines for regulatory submission and possible approval, and how might that shape the long‑term growth prospects for Biogen and Stoke Therapeutics?